https://ascopost.com/issues/march-10-2023/camrelizumabapatinib-in-recurrent-or-metastatic-nasopharyngeal-carcinoma/
Camrelizumab/Apatinib in Recurrent or Metastatic Nasopharyngeal Carcinoma - The ASCO Post
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Ding et al found that camrelizumab plus apatinib produced durable objective responses...
recurrent or metastatic
https://ascopost.com/news/july-2020/pembrolizumab-in-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma/
Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma - The ASCO Post
As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial has shown that treatment with...
recurrent or metastaticsquamous cell carcinoma
https://www.nrgoncology.org/content-block-tag/nrg-hn011-recurrent-or-metastatic-nasopharyngeal-cancer/
NRG-HN011: Recurrent or Metastatic Nasopharyngeal Cancer Archives - NRG Oncology
recurrent or metastaticnasopharyngeal cancernrgarchivesoncology
https://ascopost.com/issues/march-10-2023/camrelizumabapatinib-in-recurrent-or-metastatic-nasopharyngeal-carcinoma/
Camrelizumab/Apatinib in Recurrent or Metastatic Nasopharyngeal Carcinoma - The ASCO Post
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Ding et al found that camrelizumab plus apatinib produced durable objective responses...
recurrent or metastatic
https://www.epistemonikos.org/en/documents/3fedee251d38661b8805a641273344a9c5677954
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-n...